About this trial
The aim of this study is to validate the EmoDTx as a digital tool for mood monitoring in adult patients with unipolar depression. The study is prospective, multicenter, and observational, with a single-arm approach. The device studied, EmoDTx, is a mood-monitoring application that analyzes patients' facial expressions to assess their emotional state. The study aims to compare mood scores obtained via EmoDTx with those of standard depression questionnaires (MADRS, PHQ-9, BDI-II, HAMD-17, QIDS-SR16). It will also provide information on how patients feel about the use of passive monitoring software (without the active involvement of the patient) and how the feedback sent to patients can help in their care.
Participants who agree to take part in the study, during a selection visit, will be able to:
1. Install the software on a digital interface (smartphone, computer, etc.) and activate or deactivate it whenever they wish during the 8-week follow-up period. 2. Attend scheduled appointments at the center (a first appointment, then a second 4 weeks later, and a final at 8 weeks) to complete a series of questionnaires, be questioned by the doctor, and fill in other questionnaires on their own. 3. At home, answer questionnaires independently, 2 weeks and 6 weeks after the first appointment. 4. The application's feedback will be deactivated during the first 4 weeks and then reactivated during the final 4 weeks. 5. In parallel, an ancillary study will be conducted on 16 patients enrolled in EMC2FR who accepted and performed the video recording of their structured clinical interview following SCID-5-CV at baseline and 4 weeks.
Eligibility criteria
Qualifiers
Outpatients diagnosed with mild to severe unipolar disorder
Age ≥ 18 years old
Patients willing and able to participate (i.e willing to use the EmoDTx App and having the necessary technical equipment to use it)
Patients who read, write and understand French
Disqualifiers
Patients hospitalized
Patients taking more than 75% of the maximal recommended daily dose of benzodiazepines
Patients taking more than 75% of the maximal recommended daily dose of antipsychotics
Patients taking more than 75% of the maximal recommended daily dose of neuroleptics
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Emobot
Lead sponsor
Nîmes University Hospital
Collaborator